These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 31991614)

  • 21. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
    Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
    Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
    Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The level of deletion 17p and bi-allelic inactivation of
    Thanendrarajan S; Tian E; Qu P; Mathur P; Schinke C; van Rhee F; Zangari M; Rasche L; Weinhold N; Alapat D; Bellamy W; Ashby C; Mattox S; Epstein J; Yaccoby S; Barlogie B; Hoering A; Bauer M; Walker BA; Davies FE; Morgan GJ
    Haematologica; 2017 Sep; 102(9):e364-e367. PubMed ID: 28550191
    [No Abstract]   [Full Text] [Related]  

  • 24. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
    Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
    Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
    Feng X; Guo J; An G; Wu Y; Liu Z; Meng B; He N; Zhao X; Chen S; Zhu Y; Xia J; Li X; Yu Z; Li R; Ren G; Chen J; Wu M; He Y; Qiu L; Zhou J; Zhou W
    Adv Sci (Weinh); 2022 Mar; 9(9):e2104491. PubMed ID: 35088582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.
    De Ramón C; Rojas EA; Cardona-Benavides IJ; Mateos MV; Corchete LA; Gutiérrez NC
    Br J Haematol; 2022 Nov; 199(3):344-354. PubMed ID: 35983648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
    Gillardin PS; Descamps G; Maiga S; Tessoulin B; Djamai H; Lucani B; Chiron D; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C; Moreau-Aubry A
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
    Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
    Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.
    Stöcklein H; Smardova J; Macak J; Katzenberger T; Höller S; Wessendorf S; Hutter G; Dreyling M; Haralambieva E; Mäder U; Müller-Hermelink HK; Rosenwald A; Ott G; Kalla J
    Oncogene; 2008 Apr; 27(18):2613-25. PubMed ID: 17982487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intracranial involvement in newly diagnosed multiple myeloma with TP53 deletion: Two case reports].
    Qu S; Liao L; Xie Y; Zheng Z; Chen B
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1272-1275. PubMed ID: 30643076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
    Lionetti M; Barbieri M; Manzoni M; Fabris S; Bandini C; Todoerti K; Nozza F; Rossi D; Musto P; Baldini L; Neri A
    Oncotarget; 2016 Apr; 7(16):21353-61. PubMed ID: 26870891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
    Weinhold N; Ashby C; Rasche L; Chavan SS; Stein C; Stephens OW; Tytarenko R; Bauer MA; Meissner T; Deshpande S; Patel PH; Buzder T; Molnar G; Peterson EA; van Rhee F; Zangari M; Thanendrarajan S; Schinke C; Tian E; Epstein J; Barlogie B; Davies FE; Heuck CJ; Walker BA; Morgan GJ
    Blood; 2016 Sep; 128(13):1735-44. PubMed ID: 27516441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis.
    Abdi J; Rastgoo N; Li L; Chen W; Chang H
    J Hematol Oncol; 2017 Oct; 10(1):169. PubMed ID: 29073933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
    Singh RK; Jones RJ; Shirazi F; Qin L; Zou J; Hong S; Wang H; Lee HC; Patel KK; Wan J; Choudhary RK; Kuiatse I; Pahl A; Orlowski RZ
    Res Sq; 2024 Jan; ():. PubMed ID: 38260385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.
    Bahaj W; Kewan T; Gurnari C; Durmaz A; Ponvilawan B; Pandit I; Kubota Y; Ogbue OD; Zawit M; Madanat Y; Bat T; Balasubramanian SK; Awada H; Ahmed R; Mori M; Meggendorfer M; Haferlach T; Visconte V; Maciejewski JP
    J Hematol Oncol; 2023 Aug; 16(1):91. PubMed ID: 37537667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
    Taylor AM; Shih J; Ha G; Gao GF; Zhang X; Berger AC; Schumacher SE; Wang C; Hu H; Liu J; Lazar AJ; ; Cherniack AD; Beroukhim R; Meyerson M
    Cancer Cell; 2018 Apr; 33(4):676-689.e3. PubMed ID: 29622463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.